EU fines world’s largest generic drugmaker Teva for hindering competition
European Commission says company abused ‘dominant position’ to ‘artificially’ extend patent protection of MS medicine Copaxone
Read more at Financial Times
Topics
-
Teva Fined Around $500 Million Over MS Drug Competition Concerns
Business - The Wall Street Journal - October 31 -
EU Commission fines Teva $500M for trying to stop rival's multiple sclerosis drug
World - ABC News - October 31 -
EU Commission fines Teva $500 million for trying to stop rival's multiple sclerosis drug
Health - ABC News - October 31 -
Intel wins lengthy EU legal battle over £880m competition fine
World - The Guardian - October 24 -
World's largest crocodile in captivity dies
Top stories - BBC News - November 2 -
World’s largest coral found in the Pacific
Top stories - BBC News - November 14 -
EU leaders vow to make bloc more competitive in face of Trump threat
World - The Guardian - November 8
More from Financial Times
-
ICC issues arrest warrant for Israeli PM Netanyahu
Business - Financial Times - 27 minutes ago -
Thrive Capital: the venture firm staking billions on a few big bets
Business - Financial Times - 12 hours ago -
Trump may be right about Ukraine’s endgame
Business - Financial Times - 4 hours ago -
Mass X-odus: professionals desert Musk’s network
Business - Financial Times - 6 hours ago -
Volkswagen factory workers in Germany prepare to strike
Business - Financial Times - 11 hours ago